Literature DB >> 1469412

The IMAO-B MDL 72.974 A in Parkinson's disease.

R Marconi, A M Bonnet, M Vidailhet, Y Agid.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1469412      PMCID： PMC1015305          DOI： 10.1136/jnnp.55.11.1096-a

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  3 in total

1.  The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

Authors:  J W Tetrud; J W Langston
Journal:  Science       Date:  1989-08-04       Impact factor: 47.728

2.  MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease.

Authors:  M Zreika; J R Fozard; M W Dudley; P Bey; I A McDonald; M G Palfreyman
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1989

3.  [The L-dopa test in Parkinson's disease].

Authors:  M Esteguy; A M Bonnet; J Kefalos; F Lhermitte; Y Agid
Journal:  Rev Neurol (Paris)       Date:  1985       Impact factor: 2.607
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.